Document is current
Any future updates will be listed below
-
Authors
Słabicki, Mikołaj https://orcid.org/0000-0001-6317-9296
Yoon, Hojong https://orcid.org/0000-0002-6062-5489
Koeppel, Jonas https://orcid.org/0000-0003-1306-3994
Nitsch, Lena
Roy Burman, Shourya S. https://orcid.org/0000-0001-9274-9104
Di Genua, Cristina
Donovan, Katherine A. https://orcid.org/0000-0002-8539-5106
Sperling, Adam S.
Hunkeler, Moritz https://orcid.org/0000-0003-0246-1188
Tsai, Jonathan M.
Sharma, Rohan
Guirguis, Andrew https://orcid.org/0000-0003-3134-0596
Zou, Charles
Chudasama, Priya
Gasser, Jessica A.
Miller, Peter G.
Scholl, Claudia https://orcid.org/0000-0001-6768-322X
Fröhling, Stefan https://orcid.org/0000-0001-7907-4595
Nowak, Radosław P. https://orcid.org/0000-0002-0605-0071
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
- License Information
-
More Information
Article History
Received: 9 November 2019
Accepted: 3 September 2020
First Online: 18 November 2020
Competing interests
: B.L.E. has received research funding from Celgene and Deerfield. He has received consulting fees from GRAIL, and he serves on the scientific advisory boards for and holds equity in Skyhawk Therapeutics and Exo Therapeutics. He is a founder, member of the scientific advisory board and equity holder of Neomorph. E.S.F. is a founder, member of the scientific advisory board and equity holder of Civetta Therapeutics, Jengu Therapeutics (board member) and Neomorph, holds equity in C4 Therapeutics and is a consultant to Astellas and EcoR1 capital. The Fischer laboratory receives or has received research funding from Novartis, Deerfield, Ajax and Astellas. S.F. has had a consulting or advisory role, received honoraria, research funding and/or funding for travel or accommodation expenses from the following for-profit companies: Bayer, Roche, Amgen, Eli Lilly, PharmaMar, AstraZeneca and Pfizer. M.S., H.Y., J.K., E.S.F. and B.L.E are named as inventors on pending US Provisional Application Nos. 62/938,736 and 63/074,279, filed by The Broad Institute, Inc and Dana Farber Cancer Institute related to this work. The remaining authors declare no competing interests.
